Waltham, MA, United States of America

Edward John Hennessy

This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignee: Astrazeneca Ab. Active years: 2019-2023.

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2019-2023

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Exploring the Inventive Journey of Edward John Hennessy

Introduction:

Edward John Hennessy, a prolific inventor based in Waltham, MA (US), has made significant contributions to the field of medicine with his innovative patents. With a total of 3 patents to his name, he has been at the forefront of developing groundbreaking therapies.

Latest Patents:

One of Hennessy's recent patents includes the groundbreaking discovery of therapeutic dendrimers. These dendrimers, formulated as per a specific structure, have shown promise in treating cancer. His pharmaceutical compositions have opened new avenues in the fight against this devastating disease.

Career Highlights:

Edward John Hennessy is associated with Astrazeneca Ab, a renowned pharmaceutical company known for its cutting-edge research and development in the healthcare industry. His expertise and dedication have played a pivotal role in advancing the company's innovative ventures.

Collaborations:

Collaborating closely with esteemed colleagues such as Marianne Bernice Ashford and Iain Grant, Hennessy has been part of a dynamic team driving forward groundbreaking research initiatives. Together, they have combined their skills and knowledge to revolutionize the field of medicine.

Conclusion:

In conclusion, Edward John Hennessy stands as a testament to the power of innovation and dedication in the realm of medical advancements. His patents and collaborations reflect a commitment to pushing the boundaries of what is possible in the pursuit of improved healthcare solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…